FDA Warning Letter criticizes Supplier Qualification
CMO Supplier Qualification and the respective contracts in outsourcing activities are always hot topics in inspections. The U.S. Food and Drug Administration (FDA) recently posted a Warning Letter sent to a pharmaceutical company in the US criticizing their supplier qualification and oversight. The inspection was scheduled because of problems at the company's CMO.
For example, the company "failed to have adequate supplier qualification procedures to ensure that the drug products received" from CMOs "were manufactured in compliance with CGMP." They also "failed to have adequate procedures" to ensure tht all drug products produced for the firm met "appropriate quality attributes".
The company now has to evaluate the supplier and CMO qualification program, "including a plan to conduct periodic audits". In the Warning Letter, the FDA clearly points out that the company is responsible for the quality of the drugs "regardless of agreements in place" with CMOs.
Related GMP News
21.08.2024Warning Letter to US Company due to Lack of Product and Process Control
14.08.2024TGA introduces shorter Surveillance Inspections
31.07.2024FDA Form 483 to Chinese Manufacturer with some alarming Observations
24.07.2024FDA Warning Letter to a Manufacturer of an Athlete Muscle Maintenance Creme
24.07.2024FDA describes detailed CAPA Procedure in Warning Letter